GT Biopharma Analyst Ratings
GT Biopharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/08/2023 | 1685.71% | HC Wainwright & Co. | → $5 | Reiterates | Buy → Buy |
| 08/07/2023 | 614.29% | EF Hutton | → $2 | Reiterates | Hold → Hold |
| 06/05/2023 | 1685.71% | HC Wainwright & Co. | → $5 | Reiterates | Buy → Buy |
| 05/17/2023 | 1685.71% | HC Wainwright & Co. | → $5 | Reiterates | Buy → Buy |
| 05/16/2023 | 614.29% | EF Hutton | → $2 | Reiterates | Hold → Hold |
| 04/03/2023 | 1685.71% | HC Wainwright & Co. | → $5 | Reiterates | → Buy |
| 03/31/2023 | 614.29% | EF Hutton | → $2 | Reiterates | → Hold |
| 01/05/2023 | 614.29% | EF Hutton | → $2 | Initiates Coverage On | → Hold |
| 09/13/2022 | 1685.71% | HC Wainwright & Co. | $25 → $5 | Maintains | Buy |
| 05/24/2021 | 8828.57% | HC Wainwright & Co. | → $25 | Initiates Coverage On | → Buy |
| 04/13/2021 | 7400% | B. Riley Securities | → $21 | Initiates Coverage On | → Buy |
| 03/17/2021 | 8828.57% | Roth Capital | → $25 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 2023/08/08 | 1685.71% | HC Wainwright公司 | →$5 | 重申 | 购买→购买 |
| 08/07/2023 | 614.29% | EF Hutton | →$2 | 重申 | 保持→保持 |
| 06/05/2023 | 1685.71% | HC Wainwright公司 | →$5 | 重申 | 购买→购买 |
| 2023年05月17日 | 1685.71% | HC Wainwright公司 | →$5 | 重申 | 购买→购买 |
| 2023年05月16日 | 614.29% | EF Hutton | →$2 | 重申 | 保持→保持 |
| 04/03/2023 | 1685.71% | HC Wainwright公司 | →$5 | 重申 | →购买 |
| 03/31/2023 | 614.29% | EF Hutton | →$2 | 重申 | →保留 |
| 01/05/2023 | 614.29% | EF Hutton | →$2 | 开始承保 | →保留 |
| 09/13/2022 | 1685.71% | HC Wainwright公司 | $25→$5 | 维护 | 买 |
| 2021/05/24 | 8828.57% | HC Wainwright公司 | →$25 | 开始承保 | →购买 |
| 04/13/2021 | 7400% | B.莱利证券 | →$21 | 开始承保 | →购买 |
| 03/17/2021 | 8828.57% | 罗斯资本 | →$25 | 开始承保 | →购买 |
What is the target price for GT Biopharma (GTBP)?
GT Biophma(GTBP)的目标价格是多少？
The latest price target for GT Biopharma (NASDAQ: GTBP) was reported by HC Wainwright & Co. on August 8, 2023. The analyst firm set a price target for $5.00 expecting GTBP to rise to within 12 months (a possible 1685.71% upside). 9 analyst firms have reported ratings in the last year.
GT Biophma(纳斯达克代码：GTBP)的最新目标价是由HC Wainwright&Co.于2023年8月8日报道的。这家分析公司将目标价定为5美元，预计英镑将在12个月内上涨至(可能上涨1685.71%)。去年有9家分析公司公布了评级。
What is the most recent analyst rating for GT Biopharma (GTBP)?
GT Biophma(GTBP)的最新分析师评级是什么？
The latest analyst rating for GT Biopharma (NASDAQ: GTBP) was provided by HC Wainwright & Co., and GT Biopharma reiterated their buy rating.
GT Biophma(纳斯达克代码：GTBP)的最新分析师评级由HC Wainwright&Co.提供，GT Biophma重申其买入评级。
When is the next analyst rating going to be posted or updated for GT Biopharma (GTBP)?
GT Biophma(GTBP)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of GT Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for GT Biopharma was filed on August 8, 2023 so you should expect the next rating to be made available sometime around August 8, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与GT Biophma的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。GT Biophma的最后一次评级是在2023年8月8日提交的，所以你应该预计下一次评级将在2024年8月8日左右的某个时候提供。
Is the Analyst Rating GT Biopharma (GTBP) correct?
分析师对GT Biophma(GTBP)的评级正确吗？
While ratings are subjective and will change, the latest GT Biopharma (GTBP) rating was a reiterated with a price target of $0.00 to $5.00. The current price GT Biopharma (GTBP) is trading at is $0.28, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但GT Biophma(GTBP)的最新评级被重申，目标价在0.00美元至5.00美元之间。GT Biophma(GTBP)目前的交易价格为0.28美元，在分析师的预测范围内。